
Opinion|Videos|May 26, 2025
Current Unmet Needs in ccRCC Diagnosis
Imaging advancements in ccRCC are crucial for predicting tumor biology and enhancing treatment strategies through molecular imaging techniques.
Advertisement
Episodes in this series

Current Gaps in Renal Mass Imaging
Main Discussion Topics:
- Current imaging cannot reliably predict tumor biology or aggressiveness.
- Need for imaging techniques that can identify aggressive lesions requiring immediate intervention
- Comparison to advances in prostate cancer with molecular imaging (prostate-specific membrane antigen [PSMA] PET)
- Desire for similar molecular imaging paradigms in kidney cancer
Key Points for Physicians:
- Contemporary imaging provides anatomic and enhancement information but limited biological insights.
- The ability to predict which tumors will become aggressive remains a significant gap.
- Prostate cancer imaging has evolved to routinely include molecular imaging (PSMA PET).
- Similar developments are needed in kidney cancer imaging.
Notable Insights:
There is a significant need for imaging that predicts biological behavior rather than just providing anatomic information.
Clinical Significance:
Developing imaging that predicts tumor biology could prevent overtreatment of indolent tumors and ensure appropriate intervention for aggressive ones.
Advertisement
Related to this article

Aaron Berger, MD, discusses patient selection for ARPI treatment holidays, monitoring during interruptions, and the role of testosterone recovery in interpreting PSA kinetics.

Paras H. Shah, MD, recaps data on emerging agents in high-risk NMIBC from the 2026 AUA North Central Section Meeting.

Five-year follow-up data show durable responses with UGN-101 in patients with low-grade upper tract urothelial carcinoma who achieved an initial complete response.

Tamim Niazi, MDCM, reviews DASL-HiCaP findings showing improved metastasis-free survival with darolutamide added to ADT and radiation therapy.

Chad Ritch, MD, discusses differences between PSMA-PET imaging agents and the need for further evidence to guide clinical decision-making.

The final analysis confirmed PFS and response benefits in previously treated advanced clear cell renal cell carcinoma, but the OS difference did not cross the prespecified significance boundary.
Advertisement
Advertisement
Trending on Urology Times
1
2026 AUA North Central Section Meeting: Updates in high-risk NMIBC
2
UGN-101 shows durable responses in low-grade upper tract urothelial carcinoma
3
Tamim Niazi, MDCM, reviews darolutamide data from DASL-HiCaP
4
ESMO 2026 On Location - Why pCR is not the whole story in cisplatin-ineligible MIBC
5

